{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T12:26:48Z","timestamp":1782476808628,"version":"3.54.5"},"reference-count":169,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic & Medicinal Chemistry"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1016\/j.bmc.2024.117875","type":"journal-article","created":{"date-parts":[[2024,8,16]],"date-time":"2024-08-16T23:28:01Z","timestamp":1723850881000},"page":"117875","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Synthesis, SAR, and application of JQ1 analogs as PROTACs for cancer therapy"],"prefix":"10.1016","volume":"112","author":[{"given":"Soumik","family":"De","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raghaba","family":"Sahu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shubhendu","family":"Palei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laxmi","family":"Narayan Nanda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bmc.2024.117875_b0005","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1038\/s41557-018-0021-z","article-title":"Organic synthesis provides opportunities to transform drug discovery","volume":"10","author":"Blakemore","year":"2018","journal-title":"Nat. Chem."},{"key":"10.1016\/j.bmc.2024.117875_b0010","doi-asserted-by":"crossref","DOI":"10.1126\/science.aat0805","article-title":"The importance of synthetic chemistry in the pharmaceutical industry","volume":"363","author":"Campos","year":"2019","journal-title":"Science (80-)"},{"key":"10.1016\/j.bmc.2024.117875_b0015","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1038\/ncomms1081","article-title":"Diversity-oriented synthesis as a tool for the discovery of novel biologically active small molecules","volume":"1","author":"Galloway","year":"2010","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bmc.2024.117875_b0020","doi-asserted-by":"crossref","first-page":"e202200817","DOI":"10.1002\/ejoc.202200817","article-title":"Asymmetric Synthesis of Halocyclized Products by Using Various Catalysts: A State-of-the-Art Review","volume":"2022","author":"De","year":"2022","journal-title":"Eur. J. Org. Chem."},{"key":"10.1016\/j.bmc.2024.117875_b0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.carbpol.2023.121395","article-title":"Chitosan-based Schiff bases: Promising materials for biomedical and industrial applications","volume":"323","author":"Pawariya","year":"2024","journal-title":"Carbohydr. Polym."},{"key":"10.1016\/j.bmc.2024.117875_b0030","doi-asserted-by":"crossref","DOI":"10.1002\/asia.202200896","article-title":"Total Synthesis of Natural Products using Gold Catalysis","author":"De","year":"2022","journal-title":"Chem \u2013 an Asian J."},{"key":"10.1016\/j.bmc.2024.117875_b0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.114576","article-title":"Seeking heterocyclic scaffolds as antivirals against dengue virus","volume":"240","author":"De","year":"2022","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bmc.2024.117875_b0040","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2020.104425","article-title":"Synthetic and medicinal chemistry of phthalazines: Recent developments, opportunities and challenges","volume":"105","author":"Zaib","year":"2020","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bmc.2024.117875_b0045","doi-asserted-by":"crossref","unstructured":"Kumar Dan A, Aamna B, De S, et al. Sericin nanoparticles: Future nanocarrier for target-specific delivery of chemotherapeutic drugs. J Mol Liq. 2022;368(Part A):120717. doi:10.1016\/j.molliq.2022.120717.","DOI":"10.1016\/j.molliq.2022.120717"},{"key":"10.1016\/j.bmc.2024.117875_b0050","doi-asserted-by":"crossref","unstructured":"-H. Zhou C, Wang Y. Recent Researches in Triazole Compounds as Medicinal Drugs. Curr Med Chem. 2012;19(2):239-280. doi:10.2174\/092986712803414213.","DOI":"10.2174\/092986712803414213"},{"key":"10.1016\/j.bmc.2024.117875_b0055","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1038\/nrclinonc.2017.166","article-title":"Tumour heterogeneity and resistance to cancer therapies","volume":"15","author":"Dagogo-Jack","year":"2018","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.bmc.2024.117875_b0060","first-page":"1","article-title":"Safe and Effective Reversal of Cancer Multidrug Resistance Using Sericin-Coated Mesoporous Silica Nanoparticles for Lysosome-Targeting Delivery in Mice","volume":"13","author":"Liu","year":"2017","journal-title":"Small"},{"key":"10.1016\/j.bmc.2024.117875_b0065","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1038\/nrc.2017.36","article-title":"Drugging the \u201cundruggable\u201d cancer targets","volume":"17","author":"Dang","year":"2017","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.bmc.2024.117875_b0070","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.ejca.2017.01.035","article-title":"Cancer immunotherapy: Opportunities and challenges in the rapidly evolving clinical landscape","volume":"81","author":"Emens","year":"2017","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.bmc.2024.117875_b0075","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1007\/s10585-018-9903-0","article-title":"The challenge of drug resistance in cancer treatment: a current overview","volume":"35","author":"Nikolaou","year":"2018","journal-title":"Clin. Exp. Metastasis"},{"key":"10.1016\/j.bmc.2024.117875_b0080","doi-asserted-by":"crossref","first-page":"2010","DOI":"10.1016\/S0959-8049(99)00280-4","article-title":"Discovering novel chemotherapeutic drugs for the third millennium","volume":"35","author":"Garrett","year":"1999","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.bmc.2024.117875_b0085","doi-asserted-by":"crossref","first-page":"182","DOI":"10.2174\/156802609787521571","article-title":"Recent Advances in Medicinal Chemistry and Pharmaceutical Technology- Strategies for Drug Delivery to the Brain","volume":"9","author":"Denora","year":"2009","journal-title":"Curr. Top. Med. Chem."},{"key":"10.1016\/j.bmc.2024.117875_b0090","first-page":"7277","article-title":"Revolutionizing Cancer Treatment: Unleashing the Power of Viral Vaccines, Monoclonal Antibodies, and Proteolysis-Targeting Chimeras in the New Era of Immunotherapy","volume":"9","author":"Mohite","year":"2024","journal-title":"ACS Omega"},{"key":"10.1016\/j.bmc.2024.117875_b0095","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/s42485-023-00121-9","article-title":"Decoding cancer insights: recent progress and strategies in proteomics for biomarker discovery","volume":"15","author":"Thaddi","year":"2024","journal-title":"J Proteins Proteomics."},{"key":"10.1016\/j.bmc.2024.117875_b0100","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.cancergencyto.2010.06.007","article-title":"NUT midline carcinoma","volume":"203","author":"French","year":"2010","journal-title":"Cancer Genet. Cytogenet."},{"key":"10.1016\/j.bmc.2024.117875_b0105","doi-asserted-by":"crossref","first-page":"3235","DOI":"10.2147\/OTT.S173056","article-title":"NUT midline carcinoma of the head and neck: current perspectives","volume":"12","author":"Napolitano","year":"2019","journal-title":"Onco Targets Ther."},{"key":"10.1016\/j.bmc.2024.117875_b0110","doi-asserted-by":"crossref","first-page":"112313","DOI":"10.18632\/oncotarget.22862","article-title":"Molecular-genetic profiling and high-throughput in vitro drug screening in NUT midline carcinoma\u2014an aggressive and fatal disease","volume":"8","author":"Stirnweiss","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.bmc.2024.117875_b0115","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1186\/s13023-020-01449-x","article-title":"Clinical features, treatment, and survival outcome of primary pulmonary NUT midline carcinoma","volume":"15","author":"Xie","year":"2020","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.bmc.2024.117875_b0120","first-page":"1","article-title":"An Overview of Molecular Mechanism, Clinicopathological Factors, and Treatment in NUT Carcinoma","volume":"2019","author":"Huang","year":"2019","journal-title":"Biomed Res. Int."},{"key":"10.1016\/j.bmc.2024.117875_b0125","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1177\/107327481702400214","article-title":"NUT Midline Carcinoma: A Rare Malignancy","volume":"24","author":"Al Diffalha","year":"2017","journal-title":"Cancer Control"},{"key":"10.1016\/j.bmc.2024.117875_b0130","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1053\/j.semdp.2021.06.005","article-title":"NUT carcinoma of the lung","volume":"38","author":"Lantuejoul","year":"2021","journal-title":"Semin. Diagn. Pathol."},{"key":"10.1016\/j.bmc.2024.117875_b0135","doi-asserted-by":"crossref","first-page":"2","DOI":"10.21037\/acr-21-35","article-title":"NUT midline lung cancer: a rare case report with literature review","volume":"6","author":"Gupta","year":"2022","journal-title":"AME Case Reports."},{"key":"10.1016\/j.bmc.2024.117875_b0140","doi-asserted-by":"crossref","first-page":"S60","DOI":"10.1038\/533S60a","article-title":"Chemical probes: A shared toolbox","volume":"533","author":"Scott","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.bmc.2024.117875_b0145","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1038\/nature10334","article-title":"RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia","volume":"478","author":"Zuber","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.bmc.2024.117875_b0150","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/j.chembiol.2014.03.004","article-title":"Privileged Diazepine Compounds and Their Emergence as Bromodomain Inhibitors","volume":"21","author":"Smith","year":"2014","journal-title":"Chem. Biol."},{"key":"10.1016\/j.bmc.2024.117875_b0155","first-page":"491","article-title":"JQ1: a novel potential therapeutic target","volume":"73","author":"Shi","year":"2018","journal-title":"Die Pharm - an Int J Pharm Sci."},{"key":"10.1016\/j.bmc.2024.117875_b0160","doi-asserted-by":"crossref","DOI":"10.1002\/bies.202100180","article-title":"BRD4 in physiology and pathology: \u2018\u201cBET\u201d\u2019 on its partners","volume":"43","author":"Liang","year":"2021","journal-title":"Bioessays"},{"key":"10.1016\/j.bmc.2024.117875_b0165","doi-asserted-by":"crossref","first-page":"16","DOI":"10.3390\/biomedicines6010016","article-title":"BET Family Protein BRD4: An Emerging Actor in NF\u03baB Signaling in Inflammation and Cancer","volume":"6","author":"Hajmirza","year":"2018","journal-title":"Biomedicines."},{"key":"10.1016\/j.bmc.2024.117875_b0170","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1039\/D0RA07971E","article-title":"Bromodomain and BET family proteins as epigenetic targets in cancer therapy: their degradation, present drugs, and possible PROTACs","volume":"11","author":"Muddassir","year":"2021","journal-title":"RSC Adv."},{"key":"10.1016\/j.bmc.2024.117875_b0175","first-page":"1021","article-title":"General mechanism of JQ1 in inhibiting various types of cancer","volume":"21","author":"Jiang","year":"2020","journal-title":"Mol. Med. Rep."},{"key":"10.1016\/j.bmc.2024.117875_b0180","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.coisb.2017.05.011","article-title":"The importance of post-translational modifications in systems biology approaches to identify therapeutic targets in cancer metabolism","volume":"3","author":"Mart\u00edn-Bernab\u00e9","year":"2017","journal-title":"Curr Opin Syst Biol."},{"key":"10.1016\/j.bmc.2024.117875_b0185","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.devcel.2020.06.035","article-title":"Exploring the Influence of Cell Metabolism on Cell Fate through Protein Post-translational Modifications","volume":"54","author":"Tarazona","year":"2020","journal-title":"Dev. Cell"},{"key":"10.1016\/j.bmc.2024.117875_b0190","doi-asserted-by":"crossref","DOI":"10.1002\/mco2.292","article-title":"Post-translational modifications of histones: Mechanisms, biological functions, and therapeutic targets","volume":"4","author":"Liu","year":"2023","journal-title":"MedComm."},{"key":"10.1016\/j.bmc.2024.117875_b0195","doi-asserted-by":"crossref","first-page":"939","DOI":"10.3324\/haematol.2017.181354","article-title":"BET-inhibition by JQ1 promotes proliferation and self-renewal capacity of hematopoietic stem cells","volume":"103","author":"Wroblewski","year":"2018","journal-title":"Haematologica"},{"key":"10.1016\/j.bmc.2024.117875_b0200","doi-asserted-by":"crossref","first-page":"10738","DOI":"10.1074\/jbc.M111.323493","article-title":"Bromodomain Protein Brd4 Associated with Acetylated Chromatin Is Important for Maintenance of Higher-order Chromatin Structure","volume":"287","author":"Wang","year":"2012","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bmc.2024.117875_b0205","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.breast.2020.08.005","article-title":"The emerging role of BET inhibitors in breast cancer","volume":"53","author":"Andrikopoulou","year":"2020","journal-title":"Breast"},{"key":"10.1016\/j.bmc.2024.117875_b0210","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1002\/cbic.201000222","article-title":"Two-Headed PROTAC: An Effective New Tool for Targeted Protein Degradation","volume":"11","author":"Cyrus","year":"2010","journal-title":"Chembiochem"},{"key":"10.1016\/j.bmc.2024.117875_b0215","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1021\/acschembio.5b00216","article-title":"Selective Small Molecule Induced Degradation of the BET Bromodomain Protein BRD4","volume":"10","author":"Zengerle","year":"2015","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/j.bmc.2024.117875_b0220","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.cell.2019.11.031","article-title":"Proteolysis-Targeting Chimeras as Therapeutics and Tools for Biological Discovery","volume":"181","author":"Burslem","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.bmc.2024.117875_b0225","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1002\/med.21877","article-title":"Strategies for designing proteolysis targeting chimaeras (PROTACs)","volume":"42","author":"He","year":"2022","journal-title":"Med. Res. Rev."},{"key":"10.1016\/j.bmc.2024.117875_b0230","doi-asserted-by":"crossref","first-page":"2419","DOI":"10.1021\/acs.jmedchem.0c01487","article-title":"Targeting Bromodomain and Extraterminal Proteins for Drug Discovery: From Current Progress to Technological Development","volume":"64","author":"Tang","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bmc.2024.117875_b0235","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1007\/s11030-023-10606-w","article-title":"Recent advances in targeted protein degraders as potential therapeutic agents","volume":"28","author":"Yang","year":"2024","journal-title":"Mol. Divers."},{"key":"10.1016\/j.bmc.2024.117875_b0240","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.flm.2017.06.001","article-title":"Molecular targeted therapy of cancer: The progress and future prospect","volume":"1","author":"Ke","year":"2017","journal-title":"Front Lab Med."},{"key":"10.1016\/j.bmc.2024.117875_b0245","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1016\/j.chembiol.2017.05.024","article-title":"Targeted Protein Degradation: from Chemical Biology to Drug Discovery","volume":"24","author":"Cromm","year":"2017","journal-title":"Cell Chem. Biol."},{"key":"10.1016\/j.bmc.2024.117875_b0250","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2024.129779","article-title":"Discovery of a DCAF11-dependent cyanoacrylamide-containing covalent degrader of BET-proteins","volume":"107","author":"Tin","year":"2024","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.bmc.2024.117875_b0255","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2023.106720","article-title":"Unlocking the potential of PROTACs: A comprehensive review of protein degradation strategies in disease therapy","volume":"139","author":"Bhole","year":"2023","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bmc.2024.117875_b0260","doi-asserted-by":"crossref","first-page":"7971","DOI":"10.1039\/D2CS00478J","article-title":"PROTAC degraders as chemical probes for studying target biology and target validation","volume":"51","author":"N\u011bmec","year":"2022","journal-title":"Chem. Soc. Rev."},{"key":"10.1016\/j.bmc.2024.117875_b0265","doi-asserted-by":"crossref","first-page":"10328","DOI":"10.3390\/ijms231810328","article-title":"Recent Advances in PROTACs for Drug Targeted Protein Research","volume":"23","author":"Yao","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bmc.2024.117875_b0270","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/13543776.2021.1840553","article-title":"The therapeutic potential of PROTACs","volume":"31","author":"Benowitz","year":"2021","journal-title":"Expert Opin. Ther. Pat."},{"key":"10.1016\/j.bmc.2024.117875_b0275","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1038\/s41568-021-00365-x","article-title":"Advancing targeted protein degradation for cancer therapy","volume":"21","author":"Dale","year":"2021","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.bmc.2024.117875_b0280","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1039\/D1CB00011J","article-title":"Proteolysis targeting chimeras (PROTACs) come of age: entering the third decade of targeted protein degradation","volume":"2","author":"Bond","year":"2021","journal-title":"RSC Chem Biol."},{"key":"10.1016\/j.bmc.2024.117875_b0285","doi-asserted-by":"crossref","DOI":"10.1016\/j.crchbi.2022.100020","article-title":"Expanding the landscape of E3 ligases for targeted protein degradation","volume":"2","author":"Kramer","year":"2022","journal-title":"Curr Res Chem Biol."},{"key":"10.1016\/j.bmc.2024.117875_b0290","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1038\/s41573-019-0047-y","article-title":"Targeted protein degradation: expanding the toolbox","volume":"18","author":"Schapira","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.bmc.2024.117875_b0295","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1039\/D3CB00199G","article-title":"Click chemistry in the development of PROTACs","volume":"5","author":"Yang","year":"2024","journal-title":"RSC Chem Biol."},{"key":"10.1016\/j.bmc.2024.117875_b0300","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/j.chembiol.2020.07.020","article-title":"PROTACs: An Emerging Therapeutic Modality in Precision Medicine","volume":"27","author":"Nalawansha","year":"2020","journal-title":"Cell Chem. Biol."},{"key":"10.1016\/j.bmc.2024.117875_b0305","doi-asserted-by":"crossref","first-page":"1700247","DOI":"10.1002\/bies.201700247","article-title":"PROTACs: An Emerging Targeting Technique for Protein Degradation in Drug Discovery","volume":"40","author":"Gu","year":"2018","journal-title":"Bioessays"},{"key":"10.1016\/j.bmc.2024.117875_b0310","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.4155\/fmc-2017-0264","article-title":"Proteolysis-targeting Chimeras Mediate the Degradation of Bromodomain and extra-terminal Domain Proteins","volume":"12","author":"Yang","year":"2020","journal-title":"Future Med. Chem."},{"key":"10.1016\/j.bmc.2024.117875_b0315","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/S0014-5793(01)03309-9","article-title":"Bromodomain: an acetyl-lysine binding domain","volume":"513","author":"Zeng","year":"2002","journal-title":"FEBS Lett."},{"key":"10.1016\/j.bmc.2024.117875_b0320","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1038\/nrm.2016.143","article-title":"Functions of bromodomain-containing proteins and their roles in homeostasis and cancer","volume":"18","author":"Fujisawa","year":"2017","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.bmc.2024.117875_b0325","doi-asserted-by":"crossref","first-page":"e29","DOI":"10.1017\/S1462399411001992","article-title":"Bromodomains as therapeutic targets","volume":"13","author":"Muller","year":"2011","journal-title":"Expert Rev. Mol. Med."},{"key":"10.1016\/j.bmc.2024.117875_b0330","doi-asserted-by":"crossref","first-page":"2692","DOI":"10.1016\/j.febslet.2012.04.045","article-title":"The bromodomain interaction module","volume":"586","author":"Filippakopoulos","year":"2012","journal-title":"FEBS Lett."},{"key":"10.1016\/j.bmc.2024.117875_b0335","doi-asserted-by":"crossref","first-page":"2274","DOI":"10.3390\/v14102274","article-title":"Viral Hijacking of BET Proteins","volume":"14","author":"Chen","year":"2022","journal-title":"Viruses"},{"key":"10.1016\/j.bmc.2024.117875_b0340","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1016\/j.molcel.2020.04.034","article-title":"Opposing Functions of BRD4 Isoforms in Breast Cancer","volume":"78","author":"Wu","year":"2020","journal-title":"Mol. Cell"},{"key":"10.1016\/j.bmc.2024.117875_b0345","doi-asserted-by":"crossref","DOI":"10.3389\/fmolb.2021.728777","article-title":"The Functions of BET Proteins in Gene Transcription of Biology and Diseases","volume":"8","author":"Cheung","year":"2021","journal-title":"Front. Mol. Biosci."},{"key":"10.1016\/j.bmc.2024.117875_b0350","doi-asserted-by":"crossref","first-page":"3507","DOI":"10.1242\/dev.004481","article-title":"The first bromodomain of Brdt, a testis-specific member of the BET sub-family of double-bromodomain-containing proteins, is essential for male germ cell differentiation","volume":"134","author":"Shang","year":"2007","journal-title":"Development"},{"key":"10.1016\/j.bmc.2024.117875_b0355","doi-asserted-by":"crossref","DOI":"10.4081\/ejh.2016.2638","article-title":"The Bromodomain testis-specific gene (Brdt) characterization and expression in gilthead seabream, Sparus aurata, and European seabass, Dicentrarchus labrax","volume":"60","author":"\u00dabeda-Manzanaro","year":"2016","journal-title":"Eur. J. Histochem."},{"key":"10.1016\/j.bmc.2024.117875_b0360","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1002\/dvdy.21911","article-title":"Double bromodomain-containing gene Brd2 is essential for embryonic development in mouse","volume":"238","author":"Shang","year":"2009","journal-title":"Dev. Dyn."},{"key":"10.1016\/j.bmc.2024.117875_b0365","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1042\/BJ20090928","article-title":"Brd2 disruption in mice causes severe obesity without Type 2 diabetes","volume":"425","author":"Wang","year":"2010","journal-title":"Biochem. J"},{"key":"10.1016\/j.bmc.2024.117875_b0370","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/s41392-020-00384-4","article-title":"The BET family in immunity and disease","volume":"6","author":"Wang","year":"2021","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.bmc.2024.117875_b0375","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1002\/cmdc.201300434","article-title":"Bromodomains and Their Pharmacological Inhibitors","volume":"9","author":"Gallenkamp","year":"2014","journal-title":"ChemMedChem"},{"key":"10.1016\/j.bmc.2024.117875_b0380","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/nrc3256","article-title":"BET domain co-regulators in obesity, inflammation and cancer","volume":"12","author":"Belkina","year":"2012","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.bmc.2024.117875_b0385","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2023.108354","article-title":"BET proteins: Biological functions and therapeutic interventions","volume":"243","author":"Guo","year":"2023","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.bmc.2024.117875_b0390","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1016\/j.cell.2011.08.017","article-title":"BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-Myc","volume":"146","author":"Delmore","year":"2011","journal-title":"Cell"},{"key":"10.1016\/j.bmc.2024.117875_b0395","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1038\/nm.4379","article-title":"Intrinsic BET inhibitor resistance in SPOP-mutated prostate cancer is mediated by BET protein stabilization and AKT\u2013mTORC1 activation","volume":"23","author":"Zhang","year":"2017","journal-title":"Nat. Med."},{"key":"10.1016\/j.bmc.2024.117875_b0400","doi-asserted-by":"crossref","first-page":"1764","DOI":"10.1056\/NEJMc1211175","article-title":"Targeting Epigenetic Readers in Cancer","volume":"367","author":"Rosner","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bmc.2024.117875_b0405","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1038\/s41594-019-0309-8","article-title":"Bromodomain biology and drug discovery","volume":"26","author":"Zaware","year":"2019","journal-title":"Nat. Struct. Mol. Biol."},{"key":"10.1016\/j.bmc.2024.117875_b0410","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1038\/20974","article-title":"Structure and ligand of a histone acetyltransferase bromodomain","volume":"399","author":"Dhalluin","year":"1999","journal-title":"Nature"},{"key":"10.1016\/j.bmc.2024.117875_b0415","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1038\/nature09504","article-title":"Selective inhibition of BET bromodomains","volume":"468","author":"Filippakopoulos","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.bmc.2024.117875_b0420","doi-asserted-by":"crossref","first-page":"12921","DOI":"10.1038\/s41598-017-13036-5","article-title":"Spatially restricted loading of BRD2 at DNA double-strand breaks protects H4 acetylation domains and promotes DNA repair","volume":"7","author":"Gursoy-Yuzugullu","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bmc.2024.117875_b0425","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1016\/j.bbrc.2012.07.149","article-title":"Brd2 is required for cell cycle exit and neuronal differentiation through the E2F1 pathway in mouse neuroepithelial cells","volume":"425","author":"Tsume","year":"2012","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.bmc.2024.117875_b0430","doi-asserted-by":"crossref","first-page":"39986","DOI":"10.1038\/srep39986","article-title":"Bromodomain protein Brd3 promotes Ifnb1 transcription via enhancing IRF3\/p300 complex formation and recruitment to Ifnb1 promoter in macrophages","volume":"7","author":"Ren","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bmc.2024.117875_b0435","doi-asserted-by":"crossref","first-page":"2632","DOI":"10.1128\/MCB.05413-11","article-title":"Structural Basis and Specificity of Acetylated Transcription Factor GATA1 Recognition by BET Family Bromodomain Protein Brd3","volume":"31","author":"Gamsjaeger","year":"2011","journal-title":"Mol. Cell Biol."},{"key":"10.1016\/j.bmc.2024.117875_b0440","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1101\/gad.10.3.261","article-title":"A novel, mitogen-activated nuclear kinase is related to a Drosophila developmental regulator","volume":"10","author":"Denis","year":"1996","journal-title":"Genes Dev."},{"key":"10.1016\/j.bmc.2024.117875_b0445","doi-asserted-by":"crossref","unstructured":"Chiang CM. Brd4 engagement from chromatin targeting to transcriptional regulation: selective contact with acetylated histone H3 and H4. F1000 Biol Rep. 2009;1:98. doi:10.3410\/B1-98.","DOI":"10.3410\/B1-98"},{"key":"10.1016\/j.bmc.2024.117875_b0450","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.ddtec.2019.02.002","article-title":"A critical evaluation of the approaches to targeted protein degradation for drug discovery","volume":"31","author":"Chopra","year":"2019","journal-title":"Drug Discov. Today Technol."},{"key":"10.1016\/j.bmc.2024.117875_b0455","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112993","article-title":"PROTACs to address the challenges facing small molecule inhibitors","volume":"210","author":"Mart\u00edn-Acosta","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bmc.2024.117875_b0460","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/j.ebiom.2018.09.005","article-title":"Small-molecule PROTACs: An emerging and promising approach for the development of targeted therapy drugs","volume":"36","author":"An","year":"2018","journal-title":"EBioMedicine"},{"key":"10.1016\/j.bmc.2024.117875_b0465","doi-asserted-by":"crossref","first-page":"4909","DOI":"10.1038\/s41388-020-1336-y","article-title":"PROteolysis TArgeting Chimeras (PROTACs) as emerging anticancer therapeutics","volume":"39","author":"Khan","year":"2020","journal-title":"Oncogene"},{"key":"10.1016\/j.bmc.2024.117875_b0470","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1021\/acs.biochem.2c00245","article-title":"Molecular Glues: The Adhesive Connecting Targeted Protein Degradation to the Clinic","volume":"62","author":"Sasso","year":"2023","journal-title":"Biochemistry"},{"key":"10.1016\/j.bmc.2024.117875_b0475","doi-asserted-by":"crossref","first-page":"8554","DOI":"10.1073\/pnas.141230798","article-title":"Protacs: Chimeric molecules that target proteins to the Skp1\u2013Cullin\u2013F box complex for ubiquitination and degradation","volume":"98","author":"Sakamoto","year":"2001","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.bmc.2024.117875_b0480","doi-asserted-by":"crossref","first-page":"8428","DOI":"10.1021\/acs.jmedchem.3c00302","article-title":"Recent Advances in Pro-PROTAC Development to Address On-Target Off-Tumor Toxicity","volume":"66","author":"Chen","year":"2023","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bmc.2024.117875_b0485","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.116166","article-title":"Annual review of PROTAC degraders as anticancer agents in 2022","volume":"267","author":"Wang","year":"2024","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bmc.2024.117875_b0490","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/s41573-021-00371-6","article-title":"PROTAC targeted protein degraders: the past is prologue","volume":"21","author":"B\u00e9k\u00e9s","year":"2022","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.bmc.2024.117875_b0495","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1038\/s41594-020-0438-0","article-title":"Targeted protein degradation as a powerful research tool in basic biology and drug target discovery","volume":"27","author":"Wu","year":"2020","journal-title":"Nat. Struct. Mol. Biol."},{"key":"10.1016\/j.bmc.2024.117875_b0500","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.pharmthera.2017.02.027","article-title":"Targeted protein degradation by PROTACs","volume":"174","author":"Neklesa","year":"2017","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.bmc.2024.117875_b0505","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.coph.2021.02.009","article-title":"Transforming targeted cancer therapy with PROTACs: A forward-looking perspective","volume":"57","author":"Farnaby","year":"2021","journal-title":"Curr. Opin. Pharmacol."},{"key":"10.1016\/j.bmc.2024.117875_b0510","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.chembiol.2017.09.010","article-title":"Lessons in PROTAC Design from Selective Degradation with a Promiscuous Warhead","volume":"25","author":"Bondeson","year":"2018","journal-title":"Cell Chem. Biol."},{"key":"10.1016\/j.bmc.2024.117875_b0515","doi-asserted-by":"crossref","first-page":"3698","DOI":"10.3390\/molecules28093698","article-title":"PROTACs in the Management of Prostate Cancer","volume":"28","author":"Yedla","year":"2023","journal-title":"Molecules"},{"key":"10.1016\/j.bmc.2024.117875_b0520","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.3390\/biom12091257","article-title":"Recent Advances of Degradation Technologies Based on PROTAC Mechanism","volume":"12","author":"Xiao","year":"2022","journal-title":"Biomolecules"},{"key":"10.1016\/j.bmc.2024.117875_b0525","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/s41392-022-00999-9","article-title":"PROTACs: great opportunities for academia and industry (an update from 2020 to 2021)","volume":"7","author":"He","year":"2022","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.bmc.2024.117875_b0530","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.114290","article-title":"The state of the art of PROTAC technologies for drug discovery","volume":"235","author":"Wang","year":"2022","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bmc.2024.117875_b0535","doi-asserted-by":"crossref","first-page":"7133","DOI":"10.1038\/s41467-022-34807-3","article-title":"DeepPROTACs is a deep learning-based targeted degradation predictor for PROTACs","volume":"13","author":"Li","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bmc.2024.117875_b0540","doi-asserted-by":"crossref","first-page":"5901","DOI":"10.1021\/acsomega.2c07717","article-title":"Predictive Modeling of PROTAC Cell Permeability with Machine Learning","volume":"8","author":"Poongavanam","year":"2023","journal-title":"ACS Omega"},{"key":"10.1016\/j.bmc.2024.117875_b0545","article-title":"Revolutionizing Drug Targeting Strategies: Integrating Artificial Intelligence and Structure-Based Methods in PROTAC Development","volume":"16(12):1649","author":"Danishuddin","year":"2023","journal-title":"Pharmaceuticals."},{"key":"10.1016\/j.bmc.2024.117875_b0550","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1038\/s42256-022-00527-y","article-title":"Accelerated rational PROTAC design via deep learning and molecular simulations","volume":"4","author":"Zheng","year":"2022","journal-title":"Nat Mach Intell."},{"key":"10.1016\/j.bmc.2024.117875_b0555","first-page":"97","article-title":"The Bromodomain as an Acetyl-Lysine Reader Domain","author":"Smith","year":"2016","journal-title":"In: Chromatin Signaling and Diseases. Elsevier"},{"key":"10.1016\/j.bmc.2024.117875_b0560","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1038\/s41573-019-0030-7","article-title":"Bromodomains: a new target class for drug development","volume":"18","author":"Cochran","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.bmc.2024.117875_b0565","doi-asserted-by":"crossref","first-page":"3937","DOI":"10.1073\/pnas.73.11.3937","article-title":"Activation of chromatin by acetylation of histone side chains","volume":"73","author":"Marushige","year":"1976","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.bmc.2024.117875_b0570","doi-asserted-by":"crossref","first-page":"D261","DOI":"10.1093\/nar\/gkr1122","article-title":"PhosphoSitePlus: a comprehensive resource for investigating the structure and function of experimentally determined post-translational modifications in man and mouse","volume":"40","author":"Hornbeck","year":"2012","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.bmc.2024.117875_b0575","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1248\/cpb.c16-00225","article-title":"BET Bromodomain as a Target of Epigenetic Therapy","volume":"64","author":"Noguchi-Yachide","year":"2016","journal-title":"Chem Pharm Bull (tokyo)."},{"key":"10.1016\/j.bmc.2024.117875_b0580","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1021\/acs.organomet.9b00750","article-title":"Synthesis and Biological Investigation of (+)-JD1, an Organometallic BET Bromodomain Inhibitor","volume":"39","author":"Hassell-Hart","year":"2020","journal-title":"Organometallics"},{"key":"10.1016\/j.bmc.2024.117875_b0585","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1038\/s41419-021-03939-7","article-title":"A novel BRD4 inhibitor suppresses osteoclastogenesis and ovariectomized osteoporosis by blocking RANKL-mediated MAPK and NF-\u03baB pathways","volume":"12","author":"Liu","year":"2021","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.bmc.2024.117875_b0590","doi-asserted-by":"crossref","first-page":"601","DOI":"10.3390\/ijms19020601","article-title":"Inhibitory Effect of Purpurogallin on Osteoclast Differentiation in Vitro through the Downregulation of c-Fos and NFATc1","volume":"19","author":"Kim","year":"2018","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bmc.2024.117875_b0595","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1080\/03008207.2019.1593392","article-title":"Magnesium lithospermate B inhibits titanium particles-induced osteoclast formation by c-fos and inhibiting NFATc1 expression","volume":"60","author":"Miao","year":"2019","journal-title":"Connect. Tissue Res."},{"key":"10.1016\/j.bmc.2024.117875_b0600","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1021\/acsmedchemlett.3c00464","article-title":"Chemical Catalysis Guides Structural Identification for the Major In Vivo Metabolite of the BET Inhibitor JQ1","volume":"15","author":"Holmes","year":"2024","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.bmc.2024.117875_b0605","doi-asserted-by":"crossref","first-page":"7501","DOI":"10.1021\/jm401088k","article-title":"Discovery of Epigenetic Regulator I-BET762: Lead Optimization to Afford a Clinical Candidate Inhibitor of the BET Bromodomains","volume":"56","author":"Mirguet","year":"2013","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bmc.2024.117875_b0610","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1056\/NEJM199305133281907","article-title":"Use of Benzodiazepines in Anxiety Disorders","volume":"328","author":"Wood","year":"1993","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bmc.2024.117875_b0615","doi-asserted-by":"crossref","unstructured":"HOLLISTER LE, M??LLER-OERLINGHAUSEN B, RICKELS K, SHADER RI. Clinical Uses of Benzodiazepines. J Clin Psychopharmacol. 1993;13(Supplement):2S. doi:10.1097\/00004714-199312001-00001.","DOI":"10.1097\/00004714-199312001-00001"},{"key":"10.1016\/j.bmc.2024.117875_b0620","first-page":"225","article-title":"Meta-analysis of benzodiazepine use in the treatment of insomnia","volume":"162","author":"Holbrook","year":"2000","journal-title":"Can. Med. Assoc. J."},{"key":"10.1016\/j.bmc.2024.117875_b0625","doi-asserted-by":"crossref","first-page":"7498","DOI":"10.1021\/jm4014407","article-title":"The Making of I-BET762, a BET Bromodomain Inhibitor Now in Clinical Development","volume":"56","author":"Zhao","year":"2013","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bmc.2024.117875_b0630","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1038\/nature09589","article-title":"Suppression of inflammation by a synthetic histone mimic","volume":"468","author":"Nicodeme","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.bmc.2024.117875_b0635","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2020.115601","article-title":"Design, synthesis and biological evaluation of novel 6-phenyl-1,3a,4,10b-tetrahydro-2H-benzo[c]thiazolo[4,5-e]azepin-2-one derivatives as potential BRD4 inhibitors","volume":"28","author":"Li","year":"2020","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.bmc.2024.117875_b0640","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1021\/ml4001485","article-title":"Discovery, Design, and Optimization of Isoxazole Azepine BET Inhibitors","volume":"4","author":"Gehling","year":"2013","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.bmc.2024.117875_b0645","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1021\/acsmedchemlett.7b00389","article-title":"Design, Synthesis, and Biological Activity of 1,2,3-Triazolobenzodiazepine BET Bromodomain Inhibitors","volume":"8","author":"Sharp","year":"2017","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.bmc.2024.117875_b0650","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/j.chembiol.2015.05.009","article-title":"Hijacking the E3 Ubiquitin Ligase Cereblon to Efficiently Target BRD4","volume":"22","author":"Lu","year":"2015","journal-title":"Chem. Biol."},{"key":"10.1016\/j.bmc.2024.117875_b0655","doi-asserted-by":"crossref","unstructured":"Winter GE, Buckley DL, Paulk J, et al. Phthalimide conjugation as a strategy for in vivo target protein degradation. Science (80-). 2015;348(6241):1376-1381. doi:10.1126\/science.aab1433.","DOI":"10.1126\/science.aab1433"},{"key":"10.1016\/j.bmc.2024.117875_b0660","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1038\/nchembio.2329","article-title":"Structural basis of PROTAC cooperative recognition for selective protein degradation","volume":"13","author":"Gadd","year":"2017","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.bmc.2024.117875_b0665","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1002\/anie.201914396","article-title":"Structure-Based Design of a Macrocyclic PROTAC","volume":"59","author":"Testa","year":"2020","journal-title":"Angew Chemie Int Ed."},{"key":"10.1016\/j.bmc.2024.117875_b0670","doi-asserted-by":"crossref","first-page":"7124","DOI":"10.1073\/pnas.1521738113","article-title":"PROTAC-induced BET protein degradation as a therapy for castration-resistant prostate cancer","volume":"113","author":"Raina","year":"2016","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.bmc.2024.117875_b0675","doi-asserted-by":"crossref","first-page":"6685","DOI":"10.1021\/acs.jmedchem.8b00506","article-title":"Discovery of QCA570 as an Exceptionally Potent and Efficacious Proteolysis Targeting Chimera (PROTAC) Degrader of the Bromodomain and Extra-Terminal (BET) Proteins Capable of Inducing Complete and Durable Tumor Regression","volume":"61","author":"Qin","year":"2018","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bmc.2024.117875_b0680","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1021\/acs.jmedchem.6b01781","article-title":"A \u201cClick Chemistry Platform\u201d for the Rapid Synthesis of Bispecific Molecules for Inducing Protein Degradation","volume":"61","author":"Wurz","year":"2018","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bmc.2024.117875_b0685","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1248\/cpb.c18-00567","article-title":"Different Degradation Mechanisms of Inhibitor of Apoptosis Proteins (IAPs) by the Specific and Nongenetic IAP-Dependent Protein Eraser (SNIPER)","volume":"67","author":"Ohoka","year":"2019","journal-title":"Chem. Pharm. Bull."},{"key":"10.1016\/j.bmc.2024.117875_b0690","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.ejmech.2019.01.023","article-title":"A novel cereblon modulator for targeted protein degradation","volume":"166","author":"Kim","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bmc.2024.117875_b0695","doi-asserted-by":"crossref","first-page":"2822","DOI":"10.1021\/acschembio.9b00704","article-title":"Development of Small Molecule Chimeras That Recruit AhR E3 Ligase to Target Proteins","volume":"14","author":"Ohoka","year":"2019","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/j.bmc.2024.117875_b0700","doi-asserted-by":"crossref","first-page":"2430","DOI":"10.1021\/acschembio.8b01083","article-title":"Covalent Ligand Screening Uncovers a RNF4 E3 Ligase Recruiter for Targeted Protein Degradation Applications","volume":"14","author":"Ward","year":"2019","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/j.bmc.2024.117875_b0705","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1038\/s41589-019-0279-5","article-title":"Electrophilic PROTACs that degrade nuclear proteins by engaging DCAF16","volume":"15","author":"Zhang","year":"2019","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.bmc.2024.117875_b0710","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/j.chembiol.2021.01.005","article-title":"Chemoproteomics-enabled discovery of covalent RNF114-based degraders that mimic natural product function","volume":"28","author":"Luo","year":"2021","journal-title":"Cell Chem. Biol."},{"key":"10.1016\/j.bmc.2024.117875_b0715","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1038\/s41589-021-00878-4","article-title":"Trivalent PROTACs enhance protein degradation via combined avidity and cooperativity","volume":"17","author":"Imaide","year":"2021","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.bmc.2024.117875_b0720","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1002\/cmdc.202000249","article-title":"Controlling PROTACs with Light","volume":"15","author":"Verma","year":"2020","journal-title":"ChemMedChem"},{"key":"10.1016\/j.bmc.2024.117875_b0725","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.chempr.2022.11.007","article-title":"Photo-controllable biochemistry: Exploiting the photocages in phototherapeutic window","volume":"9","author":"Xiong","year":"2023","journal-title":"Chem"},{"key":"10.1016\/j.bmc.2024.117875_b0730","doi-asserted-by":"crossref","first-page":"18370","DOI":"10.1021\/jacs.9b06422","article-title":"Light-Induced Protein Degradation with Photocaged PROTACs","volume":"141","author":"Xue","year":"2019","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.bmc.2024.117875_b0735","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1016\/j.chembiol.2021.05.010","article-title":"Optical control of targeted protein degradation","volume":"28","author":"Reynders","year":"2021","journal-title":"Cell Chem. Biol."},{"key":"10.1016\/j.bmc.2024.117875_b0740","doi-asserted-by":"crossref","first-page":"4644","DOI":"10.1021\/acs.jmedchem.9b02058","article-title":"Azo-PROTAC: Novel Light-Controlled Small-Molecule Tool for Protein Knockdown","volume":"63","author":"Jin","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bmc.2024.117875_b0745","article-title":"Light-induced control of protein destruction by opto-PROTAC","volume":"6","author":"Liu","year":"2020","journal-title":"Sci. Adv."},{"key":"10.1016\/j.bmc.2024.117875_b0750","doi-asserted-by":"crossref","first-page":"5532","DOI":"10.1039\/D0CC00523A","article-title":"A caged E3 ligase ligand for PROTAC-mediated protein degradation with light","volume":"56","author":"Kounde","year":"2020","journal-title":"Chem. Commun."},{"key":"10.1016\/j.bmc.2024.117875_b0755","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.1021\/jacs.9b12718","article-title":"Optical Control of Small Molecule-Induced Protein Degradation","volume":"142","author":"Naro","year":"2020","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.bmc.2024.117875_b0760","doi-asserted-by":"crossref","first-page":"1682","DOI":"10.1021\/acscentsci.9b00713","article-title":"Reversible Spatiotemporal Control of Induced Protein Degradation by Bistable PhotoPROTACs","volume":"5","author":"Pfaff","year":"2019","journal-title":"ACS Cent. Sci."},{"key":"10.1016\/j.bmc.2024.117875_b0765","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.aay5064","article-title":"PHOTACs enable optical control of protein degradation","volume":"6","author":"Reynders","year":"2020","journal-title":"Sci. Adv."},{"key":"10.1016\/j.bmc.2024.117875_b0770","doi-asserted-by":"crossref","DOI":"10.1016\/j.drudis.2022.103395","article-title":"PROTAC technology: A new drug design for chemical biology with many challenges in drug discovery","volume":"28","author":"Guedeney","year":"2023","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.bmc.2024.117875_b0775","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1016\/j.bmcl.2019.04.030","article-title":"Proteolysis targeting chimeras (PROTACs) in \u2018beyond rule-of-five\u2019 chemical space: Recent progress and future challenges","volume":"29","author":"Edmondson","year":"2019","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.bmc.2024.117875_b0780","doi-asserted-by":"crossref","first-page":"13232","DOI":"10.1002\/slct.202003162","article-title":"PROTAC: A Novel Technology for Drug Development**","volume":"5","author":"Li","year":"2020","journal-title":"ChemistrySelect"},{"key":"10.1016\/j.bmc.2024.117875_b0785","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112981","article-title":"Proteolysis targeting chimera (PROTAC) in drug discovery paradigm: Recent progress and future challenges","volume":"210","author":"Zeng","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bmc.2024.117875_b0790","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1080\/17460441.2019.1659242","article-title":"PROTACs\u2013 a game-changing technology","volume":"14","author":"Konstantinidou","year":"2019","journal-title":"Expert Opin. Drug Discov."},{"key":"10.1016\/j.bmc.2024.117875_b0795","doi-asserted-by":"crossref","unstructured":"Hughes SJ, Ciulli A. Molecular recognition of ternary complexes: a new dimension in the structure-guided design of chemical degraders. van Montfort RLM, Workman P, eds. Essays Biochem. 2017;61(5):505-516. doi:10.1042\/EBC20170041.","DOI":"10.1042\/EBC20170041"},{"key":"10.1016\/j.bmc.2024.117875_b0800","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1021\/acschembio.9b00092","article-title":"SPR-Measured Dissociation Kinetics of PROTAC Ternary Complexes Influence Target Degradation Rate","volume":"14","author":"Roy","year":"2019","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/j.bmc.2024.117875_b0805","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.1803662115","article-title":"Delineating the role of cooperativity in the design of potent PROTACs for BTK","volume":"115","author":"Zorba","year":"2018","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.bmc.2024.117875_b0810","doi-asserted-by":"crossref","DOI":"10.37349\/etat.2020.00018","article-title":"Current strategies for the design of PROTAC linkers: a critical review","volume":"1","author":"Troup","year":"2020","journal-title":"Explor Target Anti-Tumor Ther."},{"key":"10.1016\/j.bmc.2024.117875_b0815","doi-asserted-by":"crossref","first-page":"5330","DOI":"10.1039\/D1CS00762A","article-title":"Proteolysis-targeting chimera (PROTAC) delivery system: advancing protein degraders towards clinical translation","volume":"51","author":"Chen","year":"2022","journal-title":"Chem. Soc. Rev."},{"key":"10.1016\/j.bmc.2024.117875_b0820","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1080\/17460441.2019.1614910","article-title":"Recent applications of click chemistry in drug discovery","volume":"14","author":"Jiang","year":"2019","journal-title":"Expert Opin. Drug Discov."},{"key":"10.1016\/j.bmc.2024.117875_b0825","doi-asserted-by":"crossref","first-page":"4014","DOI":"10.3390\/molecules28104014","article-title":"PROTACs: Emerging Targeted Protein Degradation Approaches for Advanced Druggable Strategies","volume":"28","author":"Sincere","year":"2023","journal-title":"Molecules"},{"key":"10.1016\/j.bmc.2024.117875_b0830","doi-asserted-by":"crossref","first-page":"5368","DOI":"10.3390\/molecules26175368","article-title":"Recent Advances about the Applications of Click Reaction in Chemical Proteomics","volume":"26","author":"Yao","year":"2021","journal-title":"Molecules"},{"key":"10.1016\/j.bmc.2024.117875_b0835","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1517\/17460441.2012.682725","article-title":"The impact of click chemistry in medicinal chemistry","volume":"7","author":"Hou","year":"2012","journal-title":"Expert Opin. Drug Discov."},{"key":"10.1016\/j.bmc.2024.117875_b0840","doi-asserted-by":"crossref","first-page":"7013","DOI":"10.1039\/C4CS00139G","article-title":"\u201cClick\u201d reactions: a versatile toolbox for the synthesis of peptide-conjugates","volume":"43","author":"Tang","year":"2014","journal-title":"Chem. Soc. Rev."},{"key":"10.1016\/j.bmc.2024.117875_b0845","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1016\/S1359-6446(03)02933-7","article-title":"The growing impact of click chemistry on drug discovery","volume":"8","author":"Kolb","year":"2003","journal-title":"Drug Discov. Today"}],"container-title":["Bioorganic & Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S096808962400289X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S096808962400289X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,9,10]],"date-time":"2024-09-10T01:17:59Z","timestamp":1725931079000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S096808962400289X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":169,"alternative-id":["S096808962400289X"],"URL":"https:\/\/doi.org\/10.1016\/j.bmc.2024.117875","relation":{},"ISSN":["0968-0896"],"issn-type":[{"value":"0968-0896","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Synthesis, SAR, and application of JQ1 analogs as PROTACs for cancer therapy","name":"articletitle","label":"Article Title"},{"value":"Bioorganic & Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bmc.2024.117875","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"117875"}}